For the Inventor, By the Inventor

Enter assignee name

Watertown, MA, United States of America

C4 Therapeutics, Inc.

Calculating rank

USPTO Granted Patents = 40

EPO Patents = 6

Trademarks = 8

Forward Citations = 250

Loading Chart...

Loading Chart...

58 inventors (with patents filed for the assignee):

Christopher G Nasveschuk (28 out of 66 patents)

James A Henderson (20 out of 29 patents)

Yanke Liang (20 out of 42 patents)

4. Andrew John Phillips (19 out of 49 patents)

5. Minsheng He (17 out of 29 patents)

6. Kiel Lazarski (13 out of 26 patents)

7. Annick Goergler (11 out of 27 patents)

8. Fabian Dey (10 out of 28 patents)

9. Gesine Kerstin Veits (10 out of 11 patents)

10. Roger David Norcross (10 out of 94 patents)

11. Ryan E Michael (9 out of 9 patents)

12. Martin Duplessis (9 out of 29 patents)

13. Eric Andre Kusznir (7 out of 7 patents)

14. Katrina L Jackson (7 out of 7 patents)

15. Mark E Fitzgerald (6 out of 6 patents)

Core Competencies:

Targeted Degradation

BRD9

Ikaros

BRAF

Glutarimide

Isoindolinone

Indazole

Spirocyclic Compounds

Heterocyclic Compounds

Degronimers

Dihydrobenzimidazolones

Tricyclic Ligands

40 patents: Sort by Forward Citations

1. 12746238 - Selected compounds for targeted degradation of BRD9 (2026-09-29),

2. 12729193 - TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 (2026-09-08),

3. 12721852 - Advantageous therapies for disorders mediated by Ikaros or Aiolos (2026-09-01),

4. 12662488 - Spirocyclic compounds (2026-06-23),

5. 12605450 - C3-carbon linked glutarimide Degronimers for target protein degradation (2026-04-21),

6. 12570626 - Degraders and degrons for targeted protein degradation (2026-03-10),

7. 12559492 - BRAF degraders (2026-02-24),

8. 12528797 - Heterocyclic compounds for medical treatment (2026-01-20),

9. 12486290 - Isoindolinone and indazole compounds for the degradation of EGFR (2025-12-02),

10. 12486253 - Therapeutics for the degradation of mutant BRAF (2025-12-02),

11. 12454521 - Targeted protein degradation (2025-10-28),

12. 12441740 - N/O-linked degrons and degronimers for protein degradation (2025-10-14),

13. 12421220 - Bicyclic-substituted glutarimide cereblon binders (2025-09-23),

14. 12371442 - Isoindolinone and indazole compounds for the degradation of EGFR (2025-07-29),

15. 12365681 - Dihydrobenzimidazolones for medical treatment (2025-07-22),

Company Overview

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in the development of innovative therapies for cancer treatment. The company focuses on harnessing its proprietary technology platform to create targeted protein degradation therapies, which aim to selectively eliminate disease-causing proteins. By leveraging advancements in molecular biology and drug design, C4 Therapeutics is committed to addressing unmet medical needs in oncology, enhancing treatment efficacy while minimizing side effects.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

40 Patents

#14 in Watertown, MA

#498 in Massachusetts

#8,640 in US

#17,100 in the World

Watertown, MA, United States of America

C4 Therapeutics, Inc.

Forward Citations = 250

58 inventors:

Christopher G Nasveschuk (28 out of 66 patents)

James A Henderson (20 out of 29 patents)

Yanke Liang (20 out of 42 patents)

4. Andrew John Phillips (19 out of 49 patents)

5. Minsheng He (17 out of 29 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: C4 Therapeutics, Inc.. Retrieved from https://idiyas.com/company/c4-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…